| P2093 | author name string | C Chappey | |
| | J M Whitcomb | |
| | L Kiss | |
| | C J Petropoulos | |
| | N S Hellmann | |
| | N T Parkin | |
| P2860 | cites work | Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 |
| | The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. | Q30597266 |
| | Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs | Q30621065 |
| | Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites | Q33787198 |
| | Incidence and impact of resistance against approved antiretroviral drugs | Q33966248 |
| | A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 | Q33979107 |
| | Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. | Q34288581 |
| | Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population | Q37002721 |
| | Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. | Q39651462 |
| | Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates | Q39652947 |
| | Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome | Q41649813 |
| | A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors | Q44246144 |
| | Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. | Q44252661 |
| | Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs | Q44379153 |
| | Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates | Q44598915 |
| | Clinical utility of HIV-1 genotyping and expert advice: the Havana trial | Q44647903 |
| | Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel | Q45722783 |
| | Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. | Q45734673 |
| | Antiretroviral-drug resistance among patients recently infected with HIV. | Q46277555 |
| | Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. | Q52210193 |
| | A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. | Q53977749 |
| | World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. | Q53994444 |
| | A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. | Q54044694 |
| | Drug Resistance Mutations in HIV-1 | Q73322312 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 437-443 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1 | |
| P478 | volume | 48 | |